150915-40-5 | Tirofiban HCl monohydrate

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$6.00	$4.00
5mg	98%	in stock	$8.00	$6.00
10mg	98%	in stock	$10.00	$7.00
25mg	98%	in stock	$14.00	$10.00
50mg	98%	in stock	$21.00	$15.00
250mg	98%	in stock	$53.00	$37.00
1g	98%	in stock	$133.00	$93.00
5g	98%	in stock	$446.00	$312.00

Description

• Catalog Number: AD69465
• Chemical Name: Tirofiban HCl monohydrate
• CAS Number: 150915-40-5
• Molecular Formula: C22H39ClN2O6S
• Molecular Weight: 495.0729
• MDL Number: MFCD00868210
• SMILES: CCCCS(=O)(=O)N[C@H](C(=O)O)Cc1ccc(cc1)OCCCCC1CCNCC1.O.Cl

Computed Properties

• Complexity: 579
• Covalently-Bonded Unit Count: 3
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 32
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 5
• Rotatable Bond Count: 14

Literature

• Tirofiban versus abciximab: tirofiban is administered at suboptimal dosages when evaluated in an arterial thrombosis model in non-human primates.

  Clinical and experimental medicine 20121201

• Intra-arterial tirofiban infusion for thromboembolic complication during coil embolization of ruptured intracranial aneurysms.

  European journal of radiology 20121001

• Safety and efficacy of tirofiban in stent-assisted coil embolization of intracranial aneurysms.

  Neurosurgery 20120901

• Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review.

  International journal of hematology 20120901

• Safety and efficacy of bivalirudin with glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention.

  Indian heart journal 20120901

• Two consecutive open heart operations in a small child with heparin-induced thrombocytopenia type II using anticoagulation with heparin and tirofiban.

  The Annals of thoracic surgery 20120801

• Double interruption of antiplatelet therapy and tirofiban 'bridging' for lung cancer resection.

  Minerva medica 20120801

• [High-dose tirofiban in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention].

  Zhonghua yi xue za zhi 20120724

• Intracoronary versus intravenous high-dose bolus plus maintenance administration of tirofiban in patients undergoing primary percutaneous coronary intervention for acute ST elevation myocardial infarction.

  Journal of thrombosis and thrombolysis 20120701

• GP IIb/IIIa inhibitors for STEMI: still the gold standard or an old survivor?

  Current vascular pharmacology 20120701

• Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of αIIb/β3 integrin.

  Blood 20120628

• Risk of bleeding after prehospital administration of high dose tirofiban for ST elevation myocardial infarction.

  International journal of cardiology 20120517

• Acute stent thrombosis during percutaneous coronary intervention. Treatment with tirofiban.

  Herz 20120501

• The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20120501

• Pharmacokinetic modeling of the high-dose bolus regimen of tirofiban in patients with severe renal impairment.

  Coronary artery disease 20120501

• Upstream glycoprotein IIb/IIIa inhibitors for STEMI: use on-time or not at all?

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20120501

• Additive benefit of glycoprotein IIb/IIIa inhibition and adjunctive thrombus aspiration during primary coronary intervention: results of the Initial Thrombosuction and Tirofiban Infusion (ITTI) trial.

  International journal of cardiology 20120419

• Routine upstream versus selective downstream administration of glycoprotein IIb/IIIa inhibitors in patients with non-ST-elevation acute coronary syndromes: a meta-analysis of randomized trials.

  International journal of cardiology 20120308

• Changes in BNP, hs-CRP and TIMI risk index with addition of tirofiban during primary percutaneous coronary intervention for acute STEMI: a prospective observational cohort study.

  Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology 20120301

• Treatment with tirofiban for acute coronary syndrome (ACS): a systematic review and network analysis.

  Current medical research and opinion 20120301

• Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.

  The Journal of invasive cardiology 20120301

• Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.

  JACC. Cardiovascular interventions 20120301

• The illusion of 'optimal' platelet inhibition.

  JACC. Cardiovascular interventions 20120301

• Imaging of left main coronary artery thrombus with CT coronary angiography.

  Heart, lung & circulation 20120301

• Acute myocardial infarction during the early postpartum period successfully treated with tirofiban.

  European review for medical and pharmacological sciences 20120301

• Contemporary use of glycoprotein IIb/IIIa inhibitors.

  Thrombosis and haemostasis 20120201

• [Effect of early high-loading-dose tirofiban on platelet activity in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention].

  Zhonghua xin xue guan bing za zhi 20120201

• Intracoronary bolus-only compared with intravenous bolus plus infusion of tirofiban application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20120101

• Sex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: insights from the Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study trial.

  American heart journal 20120101

• IC bolus only versus IV with infusion 2b/3a inhibitors during STEMIs having PCI.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20120101

• Direct intracoronary delivery of tirofiban during primary percutaneous coronary intervention for ST-elevation myocardial infarction.

  Chinese medical journal 20120101

• Tirofiban-induced diffuse alveolar hemorrhage: after primary angioplasty.

  Texas Heart Institute journal 20120101

• [Tirofiban improved the prognosis of senior acute coronary syndrome patients received percutaneous coronary intervention].

  Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue 20111201

• Intra-arterial tirofiban infusion for partial recanalization with stagnant flow in hyperacute cerebral ischemic stroke.

  Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences 20111201

• Current issues with glycoprotein IIb-IIIa antagonists.

  Current drug targets 20111101

• Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome.

  The American journal of cardiology 20111101

• Non-ST-segment elevation myocardial infarction in a patient with essential thrombocythemia treated with glycoprotein IIb/IIIa inhibitor: a case report.

  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20111001

• Intra-arterial adjuvant tirofiban after unsuccessful intra-arterial thrombolysis of acute ischemic stroke: preliminary experience in 16 patients.

  Neuroradiology 20111001

• RGD mimetics containing phthalimidine fragment as novel ligands of fibrinogen receptor.

  Bioorganic & medicinal chemistry letters 20111001

• Comparison of tirofiban combined with dalteparin or unfractionated heparin in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction patients.

  Chinese medical journal 20111001

• Dual oral antiplatelet therapy and unplanned surgery: possible role for intravenous platelet glycoprotein receptor inhibitors.

  Journal of cardiovascular medicine (Hagerstown, Md.) 20110901

• Safety of Tirofiban in acute Ischemic Stroke: the SaTIS trial.

  Stroke 20110901

• The antithrombotic activity of EP224283, a neutralizable dual factor Xa inhibitor/glycoprotein IIbIIIa antagonist, exceeds that of the coadministered parent compounds.

  The Journal of pharmacology and experimental therapeutics 20110801

• Delineating the roles of the GPIIb/IIIa and GP-Ib-IX-V platelet receptors in mediating platelet adhesion to adsorbed fibrinogen and albumin.

  Biomaterials 20110801

• The impact of age on effects of pre-hospital initiation of high bolus dose of tirofiban before primary angioplasty for ST-elevation myocardial infarction.

  Cardiovascular drugs and therapy 20110801

• AMI on the move.

  EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20110801

• Higher efficacy of pre-hospital tirofiban with longer pre-treatment time to primary PCI: protection for the negative impact of time delay.

  EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20110801

• Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.

  Circulation. Cardiovascular quality and outcomes 20110701

• Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab.

  Cardiovascular & hematological agents in medicinal chemistry 20110701

• Position of tirofiban in ST segment elevation myocardial infarction treatment: more than an adjunctive therapy.

  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20110701

• Controversies with On-TIME 2.

  Heart (British Cardiac Society) 20110601

• A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20110601

• Cannabis: a rare trigger of premature myocardial infarction.

  Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology 20110501

• Long-term reduction of mortality in the 4-year follow up of tirofiban therapy in elective percutaneous coronary interventions (TOPSTAR) trial.

  The Journal of invasive cardiology 20110401

• Update on glycoprotein IIb/IIIa: role in primary coronary intervention.

  Cardiovascular & hematological agents in medicinal chemistry 20110401

• Shear-dependent suppression of platelet thrombus formation by phosphodiesterase 3 inhibition requires low levels of concomitant Gs-coupled receptor stimulation.

  Thrombosis and haemostasis 20110301

• Traumatic dissection of a coronary artery: detection by multislice computed tomography and use of tirofiban as a reversible platelet inhibitor.

  Resuscitation 20110301

• Heparin versus tirofiban in microvascular anastomosis: randomized controlled trial in a rat model.

  Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale 20110201

• Upstream tirofiban reduces reperfusion cardiac arrhythmias in patients of acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.

  International journal of cardiology 20110121

• Mechanical and chemical thrombolysis of cerebral sinus thrombosis: evolution of a technique.

  Journal of neurosurgery 20110101

• Long-term efficacy of high-dose tirofiban versus double-bolus eptifibatide in patients undergoing percutaneous coronary intervention.

  Journal of cardiovascular medicine (Hagerstown, Md.) 20110101

• Promoting regeneration of peripheral nerves in-vivo using new PCL-NGF/Tirofiban nerve conduits.

  Biomaterials 20110101

• High-dose tirofiban pretreatment reduces the need for bail-out study medication in patients with ST-segment elevation myocardial infarction: results of a subgroup analysis of the On-TIME 2 trial.

  Heart (British Cardiac Society) 20110101

• Facilitated reperfusion with prehospital glycoprotein IIb/IIIa inhibition: predictors of complete ST-segment resolution before primary percutaneous coronary intervention in the On-TIME 2 trial: correlates of reperfusion before primary PCI.

  Journal of electrocardiology 20110101

• Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20110101

• Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial

  JACC. Cardiovascular interventions 20110101

• Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarc

  JACC. Cardiovascular interventions 20110101

• Failed recovery from thrombolysis is predicted by the initial diffusion weighted imaging lesion.

  Cerebrovascular diseases (Basel, Switzerland) 20110101

• Granulocyte-CSF induced inflammation-associated cardiac thrombosis in iron loading mouse heart and can be attenuated by statin therapy.

  Journal of biomedical science 20110101

• Upstream treatment of ST-segment elevation myocardial infarction: the role of glycoprotein IIb/IIIa inhibitors.

  The Canadian journal of cardiology 20110101

• Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials.

  The Canadian journal of cardiology 20110101

• Predictors and outcome of grade 3 ischemia in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

  Journal of electrocardiology 20110101

• Alveolar hemorrhage following tirofiban treatment. A misleading diagnosis.

  Revista espanola de cardiologia 20101201

• The golden hour of prehospital reperfusion with triple antiplatelet therapy: a sub-analysis from the Ongoing Tirofiban in Myocardial Evaluation 2 (On-TIME 2) trial early initiation of triple antiplatelet therapy.

  American heart journal 20101201

• Successful surgical management of massive pulmonary embolism during the second trimester in a parturient with heparin-induced thrombocytopenia.

  Interactive cardiovascular and thoracic surgery 20101101

• Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy.

  Heart (British Cardiac Society) 20101101

• Pulmonary embolectomy in heparin-induced thrombocytopenia and thrombosis? Safety of heparin use.

  Interactive cardiovascular and thoracic surgery 20101101

• Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy.

  Journal of the American College of Cardiology 20101026

• [Efficiency and safety of thrombus aspiration plus intra-infarct-related artery administration of tirofiban during primary angioplasty].

  Zhonghua xin xue guan bing za zhi 20101001

• Safety evaluation of tirofiban.

  Expert opinion on drug safety 20100901

• Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention.

  Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology 20100801

• Pharmacoinvasive strategy for ST-segment elevation myocardial infarction: wading through the treatment options.

  Circulation. Cardiovascular interventions 20100801

• Role of the paclitaxel-eluting stent and tirofiban in patients with ST-elevation myocardial infarction undergoing postfibrinolysis angioplasty: the GRACIA-3 randomized clinical trial.

  Circulation. Cardiovascular interventions 20100801

• Pre-hospital administration of tirofiban in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: a sub-analysis of the On-Time 2 trial.

  EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20100801

• Comparison by meta-analysis of eptifibatide and tirofiban to abciximab in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention.

  The American journal of cardiology 20100715

• Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial.

  European heart journal 20100701

• Randomised controlled trial evaluating the role of tirofiban in high-risk non-ST elevation acute coronary syndromes: an East Indian perspective.

  Singapore medical journal 20100701

• Early administration of small-molecule glycoprotein IIb/IIIa inhibitors before primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from randomized clinical trials.

  Journal of cardiovascular pharmacology and therapeutics 20100601

• Tirofiban 'bridging' therapy for patients with drug-eluting stents undergoing non-cardiac surgery.

  British journal of anaesthesia 20100601

• Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome.

  Journal of the American College of Cardiology 20100601

• IIb or Not IIb: is there a place for pre-hospital tirofiban in ST-segment elevation myocardial infarction patients?

  Journal of the American College of Cardiology 20100601

• Tirofiban shows better platelet inhibition in diabetic patients during PCI procedures.

  Cardiovascular journal of Africa 20100601

• Mechanism of platelet functional changes and effects of anti-platelet agents on in vivo hemostasis under different gravity conditions.

  Journal of applied physiology (Bethesda, Md. : 1985) 20100501

• Prehospital high-dose tirofiban in patients undergoing primary percutaneous intervention. The AGIR-2 study.

  Archives of cardiovascular diseases 20100501

• Thrombus aspiration plus intra-infarct-related artery administration of tirofiban improves myocardial perfusion during primary angioplasty for acute myocardial infarction.

  Chinese medical journal 20100405

• Safety of downstream high-dose tirofiban bolus among 1578 patients undergoing percutaneous coronary intervention: the Sant'ANna TIrofiban Safety study.

  Journal of cardiovascular medicine (Hagerstown, Md.) 20100401

• Tirofiban for myocardial infarction.

  Expert opinion on pharmacotherapy 20100401

• A case of acute stent thrombosis treated successfully with intracoronary tirofiban.

  Kardiologia polska 20100401

• Letter by Doraiswamy regarding article, 'Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study'.

  Circulation 20100309

• RGD-ligand mimetic antagonists of integrin alphaIIbbeta3 paradoxically enhance GPVI-induced human platelet activation.

  Journal of thrombosis and haemostasis : JTH 20100301

• Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel.

  British journal of anaesthesia 20100301

• Alveolar hemorrhage following tirofiban treatment. A misleading diagnosis.

  Revista espanola de cardiologia 20100301

• High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneous intervention.

  European journal of clinical investigation 20100201

• Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial.

  Cerebrovascular diseases (Basel, Switzerland) 20100201

• Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: the 3T/2R (Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel).

  Journal of the American College of Cardiology 20100119

• Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials.

  European heart journal 20100101

• Effect of high bolus dose tirofiban on the inflammatory response following percutaneous coronary intervention.

  Clinical cardiology 20100101

• The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention.

  The Journal of invasive cardiology 20100101

• Measuring the right compound at the right time is not always easy.

  The Journal of invasive cardiology 20100101

• Vanishing platelets: rapid and extreme tirofiban-induced thrombocytopenia after percutaneous coronary intervention for acute myocardial infarction.

  Texas Heart Institute journal 20100101

• Complete thrombus resolution with tirofiban in obstructive mechanical prosthetic mitral valve thrombosis.

  Platelets 20100101

• Successful treatment of saphenous venous graft thrombus by tirofiban infusion.

  Heart & lung : the journal of critical care 20100101

• Effects of tirofiban and percutaneous coronary intervention in an old patient with acute myocardial infarction and cardiogenic shock.

  Medicinski pregled 20100101

• The GPIIbIIIa antagonist drugs eptifibatide and tirofiban do not induce activation of apoptosis executioner caspase-3 in resting platelets but inhibit caspase-3 activation in platelets stimulated with thrombin or calcium ionophore A23187.

  Haematologica 20091201

• Tirofiban administration and percutaneous coronary intervention with stenting of saphenous vein graft thrombosis.

  Journal of cardiovascular medicine (Hagerstown, Md.) 20091101

• P-selectin antagonism reduces thrombus formation in humans.

  Journal of thrombosis and haemostasis : JTH 20091101

• Safety and efficacy of transradial vs transfemoral arterial primary coronary angioplasty for acute myocardial infarction: single-center experience.

  Circulation journal : official journal of the Japanese Circulation Society 20091101

• Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention.

  The American journal of cardiology 20091101

• Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials.

  European heart journal 20091101

• Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.

  Journal of thrombosis and haemostasis : JTH 20091001

• In vitro evaluation of ultrasound-assisted thrombolysis using a targeted ultrasound contrast agent.

  Ultrasonic imaging 20091001

• Triple antiplatelet therapy for clopidogrel resistance with stent malapposition: a case report.

  Chinese medical journal 20090920

• Integrin priming dynamics: mechanisms of integrin antagonist-promoted alphaIIbbeta3:PAC-1 molecular recognition.

  Biochemistry 20090908

• Acute inferior myocardial infarction due to cannabis smoking in a young man.

  Journal of cardiovascular medicine (Hagerstown, Md.) 20090901

• Efficacy and safety of tirofiban in high-risk patients with non-ST-segment elevation acute coronary syndromes.

  Clinical cardiology 20090901

• Acute profound thrombocytopenia after treatment with tirofiban and off-pump coronary artery bypass grafting: is there a paradox?

  The Annals of thoracic surgery 20090901

• Resolution of late sirolimus-eluting stent thrombosis after tirofiban treatment.

  Heart and vessels 20090901

• Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions.

  Chinese medical journal 20090805

• [Effect of tirofiban in acute anterior myocardial infarction patients without ST segment resolution after primary percutaneous coronary intervention].

  Zhonghua xin xue guan bing za zhi 20090801

• Tirofiban and activated protein C synergistically inhibit the Instant Blood Mediated Inflammatory Reaction (IBMIR) from allogeneic islet cells exposure to human blood.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20090701

• Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study.

  Circulation 20090630

• Effect of IIb-IIIa glycoprotein inhibitors in a partial limb amputation model submitted to warm ischemia in rats.

  Journal of reconstructive microsurgery 20090601

• Upstream high-dose tirofiban does not reduce myocardial infarct size in patients undergoing primary percutaneous coronary intervention: a magnetic resonance imaging pilot study.

  Clinical cardiology 20090601

• [The MULTISTRATEGY study].

  Giornale italiano di cardiologia (2006) 20090601

• [The FATA study].

  Giornale italiano di cardiologia (2006) 20090601

• [MULTISTRATEGY and FATA: merits, limits and troubles of no profit clinical trials in acute myocardial infarction].

  Giornale italiano di cardiologia (2006) 20090601

• A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.

  Circulation. Cardiovascular interventions 20090601

• Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis.

  Journal of the American College of Cardiology 20090505

• The benefits of platelet glycoprotein IIb/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect?

  Journal of the American College of Cardiology 20090505

• Benefit of standard versus low-dose tirofiban for percutaneous coronary intervention in very elderly patients with high-risk acute coronary syndrome.

  Acta pharmacologica Sinica 20090501

• Tirofiban increases soluble guanylate cyclase in rat vascular walls: pharmacological and pathophysiological consequences.

  Cardiovascular research 20090401

• Characterization of static adhesion of human platelets in plasma to protein surfaces in microplates.

  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20090401

• Left ventricular function after ST-elevation myocardial infarction in patients treated with primary percutaneous coronary intervention and abciximab or tirofiban (from the Facilitated Angioplasty with Tirofiban or Abciximab [FATA] Trial).

  The American journal of cardiology 20090315

• Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study.

  Journal of cardiovascular medicine (Hagerstown, Md.) 20090301

• Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20090201

• The benefits and risks of abciximab, eptifibatide, or tirofiban during PCI: class effects or do they differ?

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20090201

• Acute profound thrombocytopenia after treatment with tirofiban and off-pump coronary artery bypass grafting.

  The Annals of thoracic surgery 20090201

• Iron-induced platelet aggregation measurement: a novel method to measure platelet function in stenting for ST segment elevation myocardial infarction.

  European journal of clinical investigation 20090201

• Essential thrombocythemia: a case of acute ST-segment elevation myocardial infarction in a young female.

  Clinical cardiology 20090201

• Species differences in small molecule binding to alpha IIb beta 3 are the result of sequence differences in 2 loops of the alpha IIb beta propeller.

  Blood 20090122

• Comparison of the effects of pretreatment with tirofiban, clopidogrel or both on the inhibition of platelet aggregation and activation in patients with acute coronary syndromes.

  Journal of thrombosis and thrombolysis 20090101

• Glycoprotein IIb/IIIa inhibitor (tirofiban) in acute ST-segment elevation myocardial infarction.

  Angiology 20090101

• Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban.

  Drugs 20090101

• First report of tirofiban-induced anemia (found in combination with severe thrombocytopenia).

  Texas Heart Institute journal 20090101

• [Safety and efficacy of the use of glycoprotein IIb/IIIa inhibitors in the invasive treatment of patients with ST-elevation acute coronary syndrome].

  Kardiologiia 20090101

• [The use of tirofiban in invasive treatment of patients with non-ST-elevation acute coronary syndrome].

  Kardiologiia 20090101

• [Effects of upstream tirofiban versus downstream tirofiban on platelet aggregation and clinical outcomes in patients with high-risk acute coronary syndromes undergoing percutaneous coronary interventions].

  Zhonghua xin xue guan bing za zhi 20090101

• Earlier administration of high-dose bolus tirofiban in STEMI increases benefit without increasing bleeding complications.

  Cardiovascular journal of Africa 20090101

• Treatment of progressive stroke with tirofiban--experience in 35 patients.

  Cerebrovascular diseases (Basel, Switzerland) 20090101

• In vitro inhibition of platelet aggregation in response to increasing concentrations of tirofiban in patients with significant renal insufficiency.

  The American heart hospital journal 20090101

• Year in review 2008: Critical Care--nephrology.

  Critical care (London, England) 20090101

• Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial.

  European heart journal 20081201

• Facilitated PCI by combination fibrinolysis or upstream tirofiban in acute ST-segment elevation myocardial infarction: results of the Alteplase and Tirofiban in Acute Myocardial Infarction (ATAMI) trial.

  International journal of cardiology 20081112

• Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?

  Clinical research in cardiology : official journal of the German Cardiac Society 20081101

• Rescue treatment with intra-arterial tirofiban infusion and emergent carotid stenting.

  Yonsei medical journal 20081031

• Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome.

  Circulation journal : official journal of the Japanese Circulation Society 20081001

• Intracoronary thrombus aspiration through a guiding catheter in a case with stent thrombosis.

  The Journal of invasive cardiology 20081001

• Overcoming 'resistance' to aspirin and clopidogrel with tirofiban: fact or fiction?

  Thrombosis and haemostasis 20081001

• Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.

  Thrombosis and haemostasis 20081001

• Successful treatment of cardiogenic shock by stenting of the left main coronary artery in acute myocardial infarction.

  Vojnosanitetski pregled 20081001

• [Safety and efficacy of firebird drug-eluting stent combination tirofiban in patients with acute coronary syndrome].

  Zhonghua yi xue za zhi 20080923

• Heparin-induced thrombocytopenia and cardiopulmonary bypass: anticoagulation with unfractionated heparin and the GPIIb/IIIa inhibitor tirofiban and successful use of rFVIIa for post-protamine bleeding due to persistent platelet blockade.

  European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 20080901

• The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.

  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20080901

• Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).

  The American journal of cardiology 20080901

• Mechanical reperfusion: treat well, treat on time too.

  Lancet (London, England) 20080816

• Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial.

  Lancet (London, England) 20080816

• A strategy to offset the extra cost of sirolimus-eluting stent in patients undergoing intervention for acute myocardial infarction.

  International journal of cardiology 20080801

• Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design.

  Cardiovascular drugs and therapy 20080801

• Successful treatment of rotary pump thrombus with the glycoprotein IIb/IIIa inhibitor tirofiban.

  The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20080801

• Intra-arterial tirofiban infusion for thromboembolism during endovascular treatment of intracranial aneurysms.

  Neurosurgery 20080801

• Treatment of acute myocardial infarction in pregnancy with coronary artery balloon angioplasty and stenting: use of tirofiban and clopidogrel.

  International journal of cardiology 20080721

• Cerebellar hematoma complicating 600 mg loading dose of clopidogrel in combination with tirofiban.

  International journal of cardiology 20080721

• CABG-procedures in patients with pretreatment with the GPIIb/IIIa-receptor antagonist tirofiban (Aggrastat): modification of perioperative management?

  International journal of cardiology 20080704

• The effect of tirofiban on fibrinogen/agonist-induced platelet shape change and aggregation.

  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20080701

• Unplanned surgery after drug eluting stent implantation: a strategy for safe temporary withdrawal of dual oral antiplatelet therapy.

  Journal of cardiovascular medicine (Hagerstown, Md.) 20080701

• [Case report of acute severe thrombocytopenia induced by tirofiban].

  Zhonghua xin xue guan bing za zhi 20080701

• Transcranial Doppler ultrasonography-directed intravenous glycoprotein IIb/IIIa receptor antagonist therapy to control transient cerebral microemboli before and after carotid endarterectomy.

  The British journal of surgery 20080601

• Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

  Coronary artery disease 20080601

• The role of tirofiban in the management of coronary artery disease.

  Cardiovascular & hematological disorders drug targets 20080601

• Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  Chest 20080601

• Evaluation of triple anti-platelet therapy by modified thrombelastography in patients with acute coronary syndrome.

  Chinese medical journal 20080505

• Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.

  JAMA 20080416

• E-page Original Images. Thrombotic lesion of saphenous vein graft resolved by antiaggregant therapy.

  Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology 20080410

• Hypercoagulability due to homocystinuria in a case of head and neck reconstruction resolved with combined systemic therapy.

  Plastic and reconstructive surgery 20080401

• Efficient tirofiban infusion resulting in resolution of intracoronary thrombus.

  Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 20080401

• Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction.

  Chinese medical journal 20080320

• Synthesis and biological evaluation of PEG-tirofiban conjugates.

  Bioorganic & medicinal chemistry letters 20080315

• Real-world safety and efficacy of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.

  The Journal of invasive cardiology 20080301

• Selective inhibition of the platelet phosphoinositide 3-kinase p110beta as promising new strategy for platelet protection during extracorporeal circulation.

  Thrombosis and haemostasis 20080301

• Effects of coronary prestenting platelet inhibition on coronary poststenting inflammation.

  Journal of cardiovascular pharmacology 20080301

• Rescue use of tirofiban for acute carotid in-stent thrombosis.

  Yonsei medical journal 20080227

• Application of high-throughput screening to identify a novel alphaIIb-specific small- molecule inhibitor of alphaIIbbeta3-mediated platelet interaction with fibrinogen.

  Blood 20080201

• Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials.

  American heart journal 20080201

• High-dose tirofiban administered as bolus-only during percutaneous coronary intervention.

  The Journal of invasive cardiology 20080201

• ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy.

  The American journal of emergency medicine 20080201

• [Acute profound thrombocytopenia associated with tirofiban: clinical approach to diagnosis and therapeutic management].

  Giornale italiano di cardiologia (2006) 20080201

• Emergency coronary artery bypass grafting in patients with acute myocardial infarction treated with glycoprotein IIb/IIIa receptor inhibitors.

  International journal of cardiology 20080124

• Change of white blood cell count more prognostic important than baseline values after primary percutaneous coronary intervention for ST elevation myocardial infarction.

  Thrombosis research 20080101

• Long term tirofiban infusion before percutaneous coronary intervention in patients with angiographically massive intracoronary thrombus.

  Saudi medical journal 20080101

• Effect of platelet glycoprotein IIb/IIIa receptor antagonist on survival of epigastric island flaps in rats with total venous occlusions.

  Scandinavian journal of plastic and reconstructive surgery and hand surgery 20080101

• Liposomes/chitosan scaffold/human fibrin gel composite systems for delivering hydrophilic drugs--release behaviors of tirofiban in vitro.

  Drug delivery 20080101

• Prediction of the therapeutic index of marketed anti-coagulants and anti-platelet agents by guinea pig models of thrombosis and hemostasis.

  Thrombosis research 20080101

• Glycoprotein IIb/IIIa antagonists in acute ischaemic stroke: current status and future directions.

  Drugs 20080101

• Glycoprotein IIb/IIIa inhibitors in patients with renal insufficiency undergoing percutaneous coronary intervention.

  Cardiology in review 20080101

• Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study.

  Critical care (London, England) 20080101

• [Tirofiban or abciximab and sirolimus-eluting or bare metal uncoated stents in primary percutaneous coronary intervention for acute myocardial infarction: results of MULTISTRATEGY trial].

  Kardiologiia 20080101

• Does tirofiban prevent platelet loss in patients after cardiogenic shock during continuous renal replacement therapy?

  Critical care (London, England) 20080101

• Reduced fibrin deposition and intravascular thrombosis in hDAF transgenic pig hearts perfused with tirofiban.

  Transplantation 20071227

• Coronary embolism in a patient with mitral valve prosthesis: successful management with tirofiban and half-dose tissue-type plasminogen activator.

  Chinese medical journal 20071220

• Routine upstream versus selective down stream use of tirofiban in non-ST elevation myocardial infarction patients scheduled for early invasive therapy; a randomized comparison.

  Journal of thrombosis and thrombolysis 20071201

• [Clinical outcomes and safety of primary percutaneous coronary intervention combined with tirofiban therapy in patients with acute ST-segment elevation myocardial infarction].

  Zhonghua xin xue guan bing za zhi 20071101

• Glycoprotein IIb/IIIa antagonists during carotid artery stenting: results from the carotid artery stenting (CAS) registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK).

  Clinical research in cardiology : official journal of the German Cardiac Society 20071001

• Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).

  The American journal of cardiology 20071001

• Transfer with GP IIb/IIIa inhibitor tirofiban for primary percutaneous coronary intervention vs. on-site thrombolysis in patients with ST-elevation myocardial infarction (STEMI): a randomized open-label study for patients admitted to community hospitals.

  European heart journal 20071001

• Prevention of microsurgical anastomotic thrombosis using aspirin, heparin, and the glycoprotein IIb/IIIa inhibitor tirofiban.

  Plastic and reconstructive surgery 20071001

• Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention.

  The Canadian journal of cardiology 20071001

• Selective inhibition of platelets by the GPIIb/IIIa receptor antagonist Tirofiban reduces leukocyte-endothelial cell interaction in murine antigen-induced arthritis.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20071001

• Beta2-integrins and acquired glycoprotein IIb/IIIa (GPIIb/IIIa) receptors cooperate in NF-kappaB activation of human neutrophils.

  The Journal of biological chemistry 20070921

• Pulmonary hemorrhage in a patient with acute coronary syndrome.

  AJR. American journal of roentgenology 20070901

• Perioperative thrombotic risk of coronary artery stents: possible role for intravenous platelet blockade.

  Anesthesiology 20070901

• Influence of preparative procedures on assay of platelet function and apparent effects of antiplatelet agents.

  The American journal of cardiology 20070815

• Optimal platelet inhibition in patients undergoing PCI: data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) study.

  American heart journal 20070801

• Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study.

  Journal of the American College of Cardiology 20070710

• Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: design and rationale for the MULTI-STRATEGY trial.

  American heart journal 20070701

• Association of interleukin-10 level with increased 30-day mortality in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention.

  Circulation journal : official journal of the Japanese Circulation Society 20070701

• [Effects of intracoronary or intravenous tirofiban administration in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention].

  Zhonghua xin xue guan bing za zhi 20070601

• Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE).

  The American journal of cardiology 20070515

• A case of profound and prolonged tirofiban-induced thrombocytopenia and its correction by intravenous immunoglobulin G.

  Journal of thrombosis and haemostasis : JTH 20070501

• [Absence of benefit with triple antiaggregation in acute non persistent ST segment elevation myocardial infarction in patients not subjected to early interventionism].

  Medicina intensiva 20070501

• Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: results from TARGET (do Tirofiban and ReoPro give similar efficacy trial?).

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20070401

• Ischemic coronary syndromes and SVG Interventions--do 2b/3a inhibitors miss the target?

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20070401

• Current strategies with high-dose tirofiban.

  Expert opinion on drug metabolism & toxicology 20070401

• Evaluation on the safety and efficacy of tirofiban in the treatment of acute coronary syndrome.

  Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20070401

• AlphaIIbbeta3 priming and clustering by orally active and intravenous integrin antagonists.

  Journal of thrombosis and haemostasis : JTH 20070301

• [Update on antithrombotic treatments in arterial diseases].

  Revue medicale suisse 20070207

• Bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in drug-eluting stent implantations in the absence of acute myocardial infarction: clinical and economic results.

  The Journal of invasive cardiology 20070201

• Transvenous pacing causing tamponade in patients receiving glycoprotein IIb/IIIa inhibitors for percutaneous coronary intervention.

  The Journal of invasive cardiology 20070201

• The effects of tirofiban on peripheral markers of oxidative stress and endothelial dysfunction in patients with acute coronary syndromes.

  Thrombosis research 20070101

• Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?

  Thrombosis research 20070101

• Thrombin formation in vitro in response to shear-induced activation of platelets.

  Thrombosis research 20070101

• [Protective effects of an inhibitor of glycoprotein IIb/IIIa in the hepatic and pulmonary disturbances secondary to ischemia and reperfusion injury of rat's liver].

  Arquivos de gastroenterologia 20070101

• Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study.

  Journal of the American College of Cardiology 20061205

• Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIba.

  Thrombosis and haemostasis 20061201

• [Antithrombotic treatment of acute coronary syndromes without ST-segment elevation].

  Deutsche medizinische Wochenschrift (1946) 20061124

• [Pathogenesis and therapy of the acute coronary syndrome: differentiated advantage of glycoprotein IIb/IIIa receptor antagonists for high-risk patients].

  Deutsche medizinische Wochenschrift (1946) 20061124

• [Effect of pre-angiography use of tirofiban in patients with acute ST-elevation myocardial infarction treated by primary percutaneous coronary intervention].

  Zhonghua xin xue guan bing za zhi 20061101

• Iliac artery thrombosis after aortic balloon counterpulsation: treatment with intraarterial tirofiban, manual thrombectomy and stenting.

  International journal of cardiology 20061010

• [Platelet function after a high dose bolus of tirofiban immediately after coronary angioplasty].

  Archives des maladies du coeur et des vaisseaux 20061001

• Tirofiban-associated acute thrombocytopenia.

  Acta cardiologica 20061001

• Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative.

  Circulation 20060926

• Mitigation of device-associated thrombosis and thromboembolism using combinations of heparin and tirofiban.

  The journal of extra-corporeal technology 20060901

• Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion.

  Heart (British Cardiac Society) 20060801

• Differential diagnosis and management of acute profound thrombocytopenia by tirofiban: a case report.

  Journal of thrombosis and thrombolysis 20060801

• Complementary effects of sirolimus-eluting stents and glycoprotein IIb/IIIa inhibitors for percutaneous coronary intervention in diabetic patients: one-year follow up of a single-centre registry.

  Heart (British Cardiac Society) 20060801

• Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial.

  Circulation 20060725

• Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets.

  Circulation research 20060707

• Use of heparin upon reoperation in a pediatric patient with heparin-induced thrombocytopenia after disappearance of antibodies.

  Clinical research in cardiology : official journal of the German Cardiac Society 20060701

• In vitro effect of the potent poly(ADP-ribose) polymerase (PARP) inhibitor INO-1001 alone and in combination with aspirin, eptifibatide, tirofiban, enoxaparin or alteplase on haemostatic parameters.

  Life sciences 20060620

• Delayed stenting of a thrombotic saphenous vein graft after intravenous tirofiban pretreatment.

  International journal of cardiology 20060607

• A comparison of dual vs. triple antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndrome: results of the ELISA-2 trial.

  European heart journal 20060601

• Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era.

  The American journal of cardiology 20060601

• Utility of a whole blood single platelet counting assay to monitor the effects of tirofiban in patients with acute coronary syndromes scheduled for coronary intervention.

  Thrombosis and haemostasis 20060601

• Platelet function monitoring with the Sonoclot analyzer after in vitro tirofiban and heparin administration.

  The Journal of thoracic and cardiovascular surgery 20060601

• Role of tirofiban in treatment of stent thrombosis.

  Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology 20060601

• Acute coronary embolism after mitral valve replacement in a patient presenting with non-ST-segment elevation myocardial infarction.

  Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology 20060601

• Collagen XVII promotes integrin-mediated squamous cell carcinoma transmigration--a novel role for alphaIIb integrin and tirofiban.

  Experimental cell research 20060501

• Angiographic and clinical outcome in ST-segment elevation myocardial infarction patients receiving an adjunctive double bolus regimen of tirofiban for primary percutaneous coronary intervention.

  Circulation journal : official journal of the Japanese Circulation Society 20060501

• Platelet microaggregation inhibition in patients with acute myocardial infarction pretreated with tirofiban and relationship with angiographic and clinical outcome.

  American heart journal 20060501

• [Statistical notes. Which risks do the patient incur if his own cardiologist accepts to be involved in a clinical trial without deep consideration of the a priori available evidence?].

  Giornale italiano di cardiologia (2006) 20060501

• Comparison of abciximab with 'high-dose' tirofiban in patients undergoing percutaneous coronary intervention.

  International journal of cardiology 20060428

• Tirofiban (Aggrastat) protects platelets and decreases platelet-granulocyte binding in an extracorporeal circulation model.

  The Thoracic and cardiovascular surgeon 20060401

• A fibrin encapsulated liposomes-in-chitosan matrix (FLCM) for delivering water-soluble drugs. Influences of the surface properties of liposomes and the crosslinked fibrin network.

  International journal of pharmaceutics 20060327

• Successful lysis of coronary thrombi by long term warfarin treatment after a failed course of tirofiban infusion.

  International journal of cardiology 20060322

• A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.

  Circulation 20060321

• Direct comparison of the A to Z and PROVE IT trials: a second chance to gain a first impression.

  Circulation 20060321

• Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors.

  Journal of thrombosis and haemostasis : JTH 20060301

• Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia.

  Pharmacotherapy 20060301

• Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty.

  Heart and vessels 20060301

• Use of glycoprotein IIb/IIIa inhibitors in invasively-treated patients with non-ST elevation acute coronary syndrome.

  Journal of cardiovascular medicine (Hagerstown, Md.) 20060301

• Downstream administration of a high-dose tirofiban bolus in high-risk patients with unstable angina undergoing early percutaneous coronary intervention.

  International journal of cardiology 20060215

• Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention.

  The American journal of cardiology 20060215

• Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial.

  Journal of the American College of Cardiology 20060207

• The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis.

  Journal of the American College of Cardiology 20060207

• Upstream/downstream glycoprotein IIb/IIIa in non-ST-segment elevation myocardial infarction.

  Journal of the American College of Cardiology 20060207

• Increased ability of tirofiban to maintain its inhibitory effects on the binding of fibrinogen to platelets in blood from patients with and without diabetes mellitus.

  Coronary artery disease 20060201

• Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists.

  The American journal of cardiology 20060201

• Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5'-diphosphate receptor stimulation and cyclic calcium signaling.

  Journal of the American College of Cardiology 20060103

• Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.

  Thrombosis research 20060101

• Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.

  Thrombosis research 20060101

• Are tirofiban and abciximab identical in efficacy?

  European heart journal 20060101

• Tirofiban for the treatment of ischaemic stroke.

  Expert opinion on pharmacotherapy 20060101

• Effect of tirofiban therapy on ST segment resolution and clinical outcomes in patients with ST segment elevated acute myocardial infarction undergoing primary angioplasty.

  Cardiology 20060101

• Impacts of glycoprotein IIb/IIIa inhibition on QT dispersion after successful percutaneous coronary intervention.

  Angiology 20060101

• Impact of early tirofiban administration on myocardial salvage in patients with acute myocardial infarction undergoing infarct-related artery stenting.

  Cardiology 20060101

• Intraprocedural thrombus formation during coil placement in ruptured intracranial aneurysms: treatment with systemic application of the glycoprotein IIb/IIIa antagonist tirofiban.

  AJNR. American journal of neuroradiology 20060101

• Acute ischaemic stroke treated with combined intra-arterial thrombolysis and intravenous tirofiban despite oral anticoagulant therapy at an international normalised ratio > or = 2.0.

  Internal and emergency medicine 20060101

• [Use of heparin and platelet GPIIbIIIa inhibitor tirofiban for cardiac surgery in patients for suspicion of heparin-induced thrombocytopenia].

  Annales francaises d'anesthesie et de reanimation 20060101

• An audit of the use and complications of glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention against national UK standards.

  Cardiovascular revascularization medicine : including molecular interventions 20060101

• Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up.

  European heart journal 20051201

• Two distinct subgroups of tirofiban-induced thrombocytopenia exist due to drug dependent antibodies that cause platelet activation and increased ischaemic events.

  Platelets 20051201

• Pharmacodynamics of two different dosing regimens of tirofiban in citrate or PPACK anticoagulated blood.

  Platelets 20051201

• Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes.

  Expert opinion on drug metabolism & toxicology 20051201

• Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.

  Platelets 20051101

• Impact of ABO blood groups on tirofiban mediated inhibition of platelet function.

  Platelets 20051101

• Tirofiban plus sirolimus-eluting stent vs abciximab plus bare-metal stent.

  JAMA 20051005

• Tirofiban plus sirolimus-eluting stent vs abciximab plus bare-metal stent.

  JAMA 20051005

• Tirofiban and emergency coronary surgery.

  European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 20051001

• Intravenous tirofiban with intra-arterial urokinase and mechanical thrombolysis in stroke: preliminary experience in 11 cases.

  Stroke 20051001

• Early discharge is feasible following primary percutaneous coronary intervention with transradial stent implantation under platelet glycoprotein IIb/IIIa receptor blockade. Results of the AGGRASTENT Trial.

  The Journal of invasive cardiology 20051001

• Effect of adjunctive treatment with tirofiban on troponin T elevation during stenting of critically stenosed aortocoronary saphenous vein grafts.

  The American journal of cardiology 20050901

• Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream TIrofiban, in cath Lab Downstream Abciximab (CLOTILDA) study.

  American heart journal 20050901

• Treatment of acute central retinal artery occlusionwith the platelet glycoprotein IIb/IIIa receptor inhibitor tirofiban.

  Thrombosis and haemostasis 20050901

• Facilitated percutaneous coronary intervention (PCI) in patients with acute ST-elevation myocardial infarction: comparison of prehospital tirofiban versus fibrinolysis before direct PCI.

  International journal of cardiology 20050818

• [Effects of anti-platelet drugs on myocardial no-reflow after acute myocardial infarction and reperfusion: experiment with mini-swine model].

  Zhonghua yi xue za zhi 20050817

• Impact of platelet glycoprotein IIb/IIIa Inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy).

  The American journal of cardiology 20050815

• A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome.

  The Journal of invasive cardiology 20050801

• Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting.

  American heart journal 20050801

• Variation in the ability of glycoprotein IIb-IIIa antagonists to exert and maintain their inhibitory effects on the binding of fibrinogen.

  Journal of cardiovascular pharmacology 20050701

• Compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050701

• The effect of tirofiban on microvascular thrombosis: crush model.

  Plastic and reconstructive surgery 20050701

• Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial.

  American heart journal 20050701

• Ability of different glycoprotein IIb-IIIa ligands to support platelet aggregation induced by activating antibody CRC54.

  Biochemistry. Biokhimiia 20050701

• Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome.

  European heart journal 20050601

• Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial).

  The American journal of cardiology 20050601

• Simultaneous integrin alphavbeta3 and glycoprotein IIb/IIIa inhibition causes reduction in infarct size in a model of acute coronary thrombosis and primary angioplasty.

  Cardiovascular research 20050601

• Safety of tirofiban therapy in korean patients with acute coronary syndrome.

  Circulation journal : official journal of the Japanese Circulation Society 20050601

• The impact of GP IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients.

  The Journal of invasive cardiology 20050601

• Platelet glycoprotein IIb/IIIa inhibition as adjunctive therapy during primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.

  The Journal of invasive cardiology 20050601

• Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial.

  JAMA 20050504

• The effect of tirofiban and clopidogrel pretreatment on outcome of old saphenous vein graft stenting in patients with acute coronary syndromes.

  The Tohoku journal of experimental medicine 20050501

• Delayed tirofiban-induced thrombocytopenia: two case reports.

  Journal of thrombosis and haemostasis : JTH 20050501

• Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction.

  Thrombosis and haemostasis 20050501

• The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial.

  American heart journal 20050501

• Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study.

  International journal of cardiology 20050408

• Hyperglycemia is an important predictor of impaired coronary flow before reperfusion therapy in ST-segment elevation myocardial infarction.

  Journal of the American College of Cardiology 20050405

• Leukocyte-platelet aggregates in rat peripheral blood after ischemic stroke and reperfusion.

  Biological research for nursing 20050401

• Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, with tirofiban in healthy volunteers.

  Thrombosis and haemostasis 20050401

• Choice of GPIIb/IIIa antagonist in percutaneous coronary intervention: how should economic criteria be factored in?

  Pharmacy world & science : PWS 20050401

• Is platelet function as measured by Thrombelastograph monitoring in whole blood affected by platelet inhibitors?

  The journal of extra-corporeal technology 20050301

• Tirofiban in acute coronary syndromes.

  Expert review of cardiovascular therapy 20050301

• Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial infarction.

  American heart journal 20050301

• Long-term clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome.

  Circulation journal : official journal of the Japanese Circulation Society 20050201

• Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors.

  Chest 20050201

• Combination of a high bolus dose of tirofiban with half-dose thrombolytics for the treatment of subacute stent thrombosis.

  Acta cardiologica 20050201

• Effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and soluble CD40 ligand following percutaneous coronary interventions in patients with stable coronary artery disease.

  The American journal of cardiology 20050115

• [Spleen rupture in myocardial infarction after administration of GP IIb-IIIa-antagonists].

  Deutsche medizinische Wochenschrift (1946) 20050107

• Intra-arterial thrombolysis for acute ischemic stroke: preliminary experience with platelet glycoprotein IIb/IIIa inhibitors as adjunctive therapy.

  Neurosurgery 20050101

• Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease.

  The American journal of cardiology 20050101

• Safety of tirofiban therapy in very old patients with acute coronary syndrome or non-Q-wave myocardial infarction.

  Journal of the American Geriatrics Society 20050101

• Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: a review and guide to patient selection.

  Drugs 20050101

• FK419, a novel nonpeptide GPIIb/IIIa antagonist, restores microvascular patency and improves outcome in the guinea-pig middle cerebral artery thrombotic occlusion model: comparison with tirofiban.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20050101

• Combining the hDAF transgene with the GP IIb/IIIa inhibitor tirofiban improves heart performance and reduces myocardial damage following hyperacute rejection in an ex vivo perfusion model.

  Transplantation proceedings 20050101

• Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.

  Thrombosis research 20050101

• Restoration of normal coronary flow with tirofiban by intracoronary administration for no-reflow phenomenon after stent deployment.

  International heart journal 20050101

• Profound thrombocytopenia associated with tirofiban: case report and review of literature.

  Angiology 20050101

• Is platelet adhesion assay able to quantify drug-induced platelet dysfunction?

  Seminars in thrombosis and hemostasis 20050101

• Antiplatelet agents in patients undergoing percutaneous coronary intervention: how many and how much?

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20050101

• Intravenous glycoprotein IIb/IIIa inhibitor (tirofiban) followed by intra-arterial urokinase and mechanical thrombolysis in stroke.

  AJNR. American journal of neuroradiology 20050101

• Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.

  The American journal of cardiology 20041215

• Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?

  Journal of clinical pharmacy and therapeutics 20041201

• N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes.

  Circulation 20041116

• Evaluation of bleeding complications associated with glycoprotein IIb/IIIa inhibitors.

  The Annals of pharmacotherapy 20041101

• Effects of tirofiban on acute systemic inflammatory response in elective percutaneous coronary interventions.

  Current medical research and opinion 20041101

• The effect of tirofiban on ST segment resolution in patients with non-ST elevated myocardial infarction.

  Japanese heart journal 20041101

• Von Willebrand factor can support platelet aggregation via interaction with activated GPIIb-IIIa and GPIb.

  Platelets 20041101

• Repetitive profound thrombocytopenia after treatment with tirofiban: a case report.

  Cardiovascular drugs and therapy 20041101

• Extracorporeal elimination of large concentrations of tirofiban by zero-balanced ultrafiltration during cardiopulmonary bypass: an in vitro investigation.

  Anesthesia and analgesia 20041001

• Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial.

  European heart journal 20041001

• Thrombocytopenia resulting from sensitivity to GPIIb-IIIa inhibitors.

  Seminars in thrombosis and hemostasis 20041001

• Elevations in troponin I after percutaneous coronary interventions are associated with abnormal tissue-level perfusion in high-risk patients with non-ST-segment-elevation acute coronary syndromes.

  Circulation 20040921

• Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.

  Journal of the American College of Cardiology 20040915

• Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS).

  The American journal of cardiology 20040915

• Platelet function predicts myocardial damage in patients with acute myocardial infarction.

  Circulation 20040914

• Practical approach to the diagnosis and management of thrombocytopenia associated with tirofiban treatment.

  American journal of hematology 20040901

• Impact of invasive strategy for the management of patients with cardiogenic shock after acute myocardial infarction.

  Coronary artery disease 20040901

• An image of coronary thrombus mimicking dissection detected by intravascular ultrasound during functional evaluation of an intermediate lesion.

  The Journal of invasive cardiology 20040901

• Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.

  Circulation 20040824

• Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy).

  The American journal of cardiology 20040815

• Effects of tirofiban on haemostatic activation in vitro.

  British journal of anaesthesia 20040801

• Continuous tenecteplase infusion combined with peri/postprocedural platelet glycoprotein IIb/IIIa inhibition in peripheral arterial thrombolysis: initial safety and feasibility experience.

  Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists 20040801

• Cilostazol inhibits platelet-leukocyte interaction by suppression of platelet activation.

  Platelets 20040801

• Does clopidogrel increase the degree of platelet inhibition when a platelet glycoprotein IIb/IIIa inhibitor has been given? Insights from an optical platelet aggregometry study.

  Journal of thrombosis and thrombolysis 20040801

• Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions.

  Journal of the American College of Cardiology 20040721

• The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial.

  Journal of the American College of Cardiology 20040707

• Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.

  JAMA 20040707

• Use of the early invasive approach in the management of acute coronary syndromes.

  Current cardiology reports 20040701

• Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention.

  Heart (British Cardiac Society) 20040701

• Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function.

  The American journal of cardiology 20040701

• The effect of combined thrombolysis with rtPA and tirofiban on ischemic brain lesions.

  Neurology 20040608

• Determination of Tirofiban in human serum by liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040605

• Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion.

  The American journal of cardiology 20040601

• Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study).

  The American journal of cardiology 20040515

• Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.

  Circulation 20040511

• Detection of acutely impaired microvascular reperfusion after infarct angioplasty with magnetic resonance imaging.

  Circulation 20040504

• Glycoprotein IIb/IIIa inhibitors increase COAT-platelet production in vitro.

  The Journal of laboratory and clinical medicine 20040501

• Tirofiban for catheter intervention in acute myocardial infarction?

  European heart journal 20040501

• Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial.

  European heart journal 20040501

• Successful recanalization of an occluded coronary artery by percutaneous coronary intervention, systemic administration of tirofiban, a glycoprotein IIb/IIIa inhibitor, and intracoronary thrombolysis with alteplase.

  Zeitschrift fur Kardiologie 20040501

• Inhibition of streptokinase-induced, antibody-mediated platelet aggregation with tirofiban after exposure to streptokinase or streptococcal infection.

  Pharmacotherapy 20040501

• High-dose bolus tirofiban and sirolimus eluting stent versus abiciximab and bare metal stent in acute myocardial infarction (STRATEGY) study--protocol design and demography of the first 100 patients.

  Cardiovascular drugs and therapy 20040501

• Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction.

  Kardiologia polska 20040501

• Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial.

  The American journal of cardiology 20040401

• Effectiveness of tirofiban for failed thrombolysis during acute myocardial infarction.

  The American journal of cardiology 20040401

• Transradial application of PercuSurge GuardWire device during primary percutaneous intervention of infarct-related artery with high-burden thrombus formation.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20040401

• Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial.

  American heart journal 20040401

• Characterization and metal affinity of Tirofiban, a pharmaceutical compound used in acute coronary syndromes.

  Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine 20040401

• Safety and feasibility of a novel dosing regimen of tirofiban administered in patients with acute myocardial infarction with ST elevation before primary coronary angioplasty: a pilot study.

  Journal of thrombosis and thrombolysis 20040401

• [Efficacy and safety of treatment of acute ischemic stroke with glycoprotein IIb/IIIa receptor blocker in routine clinical practice].

  Deutsche medizinische Wochenschrift (1946) 20040319

• Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion.

  Stroke 20040301

• Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa inhibitors.

  Current hematology reports 20040301

• Massive pulmonary haemorrhage complicating the treatment of acute coronary syndrome.

  Heart (British Cardiac Society) 20040301

• Glycoprotein IIb-IIIa antagonists in non-ST elevation acute coronary syndromes and percutaneous interventions: from pharmacology to individual patient's therapy: part 1: the evidence of benefit.

  Journal of cardiovascular pharmacology 20040301

• Intravenous glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: lessons from recently conducted randomized clinical trials.

  Current opinion in investigational drugs (London, England : 2000) 20040301

• Treatment of intracoronary thrombus using tirofiban in a patient with normal coronary arteries.

  Japanese heart journal 20040301

• [Pharmacologic therapy in failed thrombolysis: sequential infusion of tirofiban. Pilot study with 47 patients].

  Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace 20040301

• Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.

  Circulation 20040224

• Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy.

  Circulation 20040210

• Safety of a high bolus dose of tirofiban in patients undergoing coronary stent placement.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20040201

• Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction.

  The American journal of cardiology 20040201

• Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes.

  Platelets 20040201

• Tirofiban and eptifibatide treatment of patients presenting with acute coronary syndrome with non-ST segment elevation.

  Pharmacy world & science : PWS 20040201

• Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion. A quantitative myocardial contrast echocardiography study.

  Journal of the American College of Cardiology 20040121

• Glycoprotein IIb/IIIa inhibitors and no-reflow.

  Journal of the American College of Cardiology 20040121

• Effect of tirofiban on C-reactive protein in non-ST-elevation myocardial infarction.

  American heart journal 20040101

• Diffuse alveolar hemorrhage following administration of tirofiban in a patient with acute coronary syndrome: a fatal complication.

  International journal of cardiology 20040101

• Effect of adjunctive tirofiban therapy on angiographic and clinical outcomes in patients with ST-segment elevated acute myocardial infarction undergoing primary stenting.

  Japanese heart journal 20040101

• Acute myocardial infarction in a patient with essential thrombocythemia treated with glycoprotein IIb/IIIa inhibitor.

  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20040101

• Effects of glycoprotein IIb/IIIa receptor inhibition with tirofiban on minor myocardial damage in angiographically successful percutaneous coronary angioplasty.

  Cardiology 20040101

• Therapeutics of platelet glycoprotein IIb/IIIa receptor antagonism.

  American journal of therapeutics 20040101

• Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin.

  Blood 20031215

• Effect of the PercuSurge GuardWire device on the integrity of microvasculature and clinical outcomes during primary transradial coronary intervention in acute myocardial infarction.

  The American journal of cardiology 20031201

• Blockade of GPIIb/IIIa by eptifibatide and tirofiban does not alter tissue factor induced thrombin generation in human endotoxemia.

  Thrombosis and haemostasis 20031201

• The effect of glycoprotein IIb/IIIa receptor inhibitor on the microcirculation in patients undergoing high-risk coronary stenting; a prospective, randomized study.

  Journal of thrombosis and thrombolysis 20031201

• Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation.

  The American journal of cardiology 20031101

• Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention.

  American heart journal 20031101

• Effects of 2 different antiplatelet regimens with abciximab or tirofiban on platelet function in patients undergoing coronary stenting.

  American heart journal 20031101

• Use of lepirudin during percutaneous vascular interventions in patients with heparin-induced thrombocytopenia.

  The Journal of invasive cardiology 20031101

• Effects of enoxaparin and nadroparin on major cardiac events in high-risk unstable angina treated with a glycoprotein IIb/IIIa inhibitor.

  Japanese heart journal 20031101

• Prospective evaluation of clinical outcomes after acute ST-elevation myocardial infarction in patients who are ineligible for reperfusion therapy: preliminary results from the TETAMI registry and randomized trial.

  Circulation 20031021

• Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction.

  The American journal of cardiology 20031015

• The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.

  Journal of the American College of Cardiology 20031015

• Optimizing outcomes in ST-segment elevation myocardial infarction.

  Journal of the American College of Cardiology 20031015

• Isolation of a Zn-binding protein mediating cell adhesion from common carp.

  Biochemical and biophysical research communications 20031003

• Outcomes with changes in prescribing of glycoprotein IIb/IIIa inhibitors in PCI.

  The Annals of pharmacotherapy 20031001

• Evidence of platelet activation due to tirofiban-dependent platelet antibodies: double trouble.

  Journal of thrombosis and haemostasis : JTH 20031001

• Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET).

  Journal of the American College of Cardiology 20031001

• Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition?

  Journal of the American College of Cardiology 20031001

• National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom.

  International journal of cardiology 20031001

• Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.

  American heart journal 20031001

• Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).

  American heart journal 20031001

• [Role of GP IIb/IIIa blockers in clinical cardiology].

  Recenti progressi in medicina 20031001

• Evaluation of prolonged antithrombotic pretreatment ('cooling-off' strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial.

  JAMA 20030924

• Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial.

  Journal of the American College of Cardiology 20030917

• Angiographic predictors of adverse outcomes in the modern interventional era.

  Journal of the American College of Cardiology 20030917

• Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity.

  Journal of thrombosis and haemostasis : JTH 20030901

• Impact of tirofiban on angiographic morphologic features of high-burden thrombus formation during direct percutaneous coronary intervention and short-term outcomes.

  Chest 20030901

• Beta brachytherapy of an old degenerated saphenous vein graft with occlusive in-stent restenosis.

  Italian heart journal : official journal of the Italian Federation of Cardiology 20030901

• Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease.

  Circulation 20030805

• Thrombolysis with recombinant tissue plasminogen activator and tirofiban in stroke: preliminary observations.

  Stroke 20030801

• A comparison of two invasive strategies in patients with non-ST elevation acute coronary syndromes: results of the Early or Late Intervention in unStable Angina (ELISA) pilot study. 2b/3a upstream therapy and acute coronary syndromes.

  European heart journal 20030801

• [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].

  Herz 20030801

• Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes--observations from the TARGET trial.

  The American journal of cardiology 20030715

• Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.

  Heart and vessels 20030701

• [Update cardiology 2001/2002-part II. From unstable coronary syndrome to terminal heart failure].

  Medizinische Klinik (Munich, Germany : 1983) 20030615

• Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20030615

• Cerebral microembolism is blocked by tirofiban, a selective nonpeptide platelet glycoprotein IIb/IIIa receptor antagonist.

  Circulation 20030603

• Synergism of aspirin and heparin with a low-frequency non-invasive ultrasound system for augmentation of in-vitro clot lysis.

  Journal of thrombosis and thrombolysis 20030601

• Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment.

  Heart (British Cardiac Society) 20030501

• Dissolution of a huge spontaneous coronary artery thrombus with a new antiplatelet agent and coronary angioplasty.

  International journal of cardiology 20030501

• A propensity analysis of the impact of platelet glycoprotein IIb/IIIa inhibitor therapy on in-hospital outcomes after percutaneous coronary intervention.

  The American journal of cardiology 20030415

• Association of an activated clotting time < or =250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TACTICS-TIMI 18 substudy).

  The American journal of cardiology 20030415

• Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates.

  Journal of cardiovascular pharmacology 20030401

• Effects of GP IIb/IIIa receptor inhibitor tirofiban (aggrastat) in ex vivo canine arteriovenous shunt model of stent thrombosis.

  Journal of cardiovascular pharmacology 20030401

• Suboptimal inhibition of platelet aggregation following tirofiban bolus in patients undergoing percutaneous coronary intervention for unstable angina pectoris.

  The American journal of cardiology 20030401

• Use of platelet glycoprotein IIb/IIIa inhibitors and spontaneous pulmonary hemorrhage.

  The Journal of invasive cardiology 20030401

• Cytokine response after percutaneous coronary intervention in stable angina: effect of selective glycoprotein IIb/IIIa receptor antagonism.

  American heart journal 20030401

• Management of heparin resistance during cardiopulmonary bypass: the effect of five different anticoagulation strategies on hemostatic activation.

  Journal of cardiothoracic and vascular anesthesia 20030401

• [GP IIb/IIIa receptor prevention medicine].

  Nihon rinsho. Japanese journal of clinical medicine 20030401

• Value of thromboelastography in the assessment of platelet function.

  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20030401

• Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial.

  Circulation 20030325

• Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.

  Circulation 20030304

• Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation.

  Blood 20030301

• Preoperative platelet inhibition and bleeding after cardiopulmonary bypass.

  The Journal of thoracic and cardiovascular surgery 20030301

• Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.

  Zeitschrift fur Kardiologie 20030301

• The thrombolysis in myocardial infarction risk score in unstable angina/non-ST-segment elevation myocardial infarction.

  Journal of the American College of Cardiology 20030219

• Thrombocytopenia following treatment with platelet glycoprotein IIb/IIIa inhibitors.

  Blood 20030215

• Interactions between age, outcome of acute coronary syndromes, and tirofiban therapy.

  The American journal of cardiology 20030215

• Comparison of the i-STAT handheld activated clotting time with the Hemochron activated clotting time during and after percutaneous coronary intervention.

  The American journal of cardiology 20030215

• Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban.

  The American journal of cardiology 20030201

• Effects of tirofiban on hemostatic activation and inflammatory response during cardiopulmonary bypass.

  The American journal of cardiology 20030201

• Effect of fibrinogen concentration and platelet count on the inhibitory effect of abciximab and tirofiban.

  Thrombosis and haemostasis 20030201

• Access to new cardiovascular therapies in Canadian hospitals: a national survey of the formulary process.

  The Canadian journal of cardiology 20030201

• Evaluation of glycoprotein IIb/IIIa inhibitors in carotid angioplasty and stenting.

  Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists 20030201

• Adjunctive use of platelet glycoprotein IIb/IIIa inhibitors for carotid angioplasty and stent placement: time to say good bye?

  Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists 20030201

• [Angiogram of the month].

  Kardiologia polska 20030201

• Endothelin-1 induced proinflammatory markers in the myocardium and leukocytes of guinea-pigs: role of glycoprotein IIB/IIIA receptors.

  Cardiovascular research 20030101

• Outcome of access site in patients treated with platelet glycoprotein IIb/IIIa inhibitors in the era of closure devices.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20030101

• Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20030101

• Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions.

  Journal of the American College of Cardiology 20030101

• [New antiaggregants and their importance for the practitioner].

  Therapeutische Umschau. Revue therapeutique 20030101

• Preliminary experience with a high bolus dose of tirofiban during percutaneous coronary intervention.

  Current medical research and opinion 20030101

• Use of abciximab and tirofiban in patients with peripheral arterial occlusive disease and arterial thrombosis.

  Angiology 20030101

• Differential benefits and outcomes of tirofiban vs abciximab for acute coronary syndromes in current clinical practice.

  Angiology 20030101

• Prolonged systemic delivery of tirofiban in a thrombus-laden saphenous vein graft.

  International journal of cardiovascular interventions 20030101

• Risk-benefit analysis of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.

  Expert opinion on drug safety 20030101

• Retroperitoneal hematoma following tirofiban and enoxaparin coadministration in a patient with acute coronary syndrome.

  Thrombosis research 20030101

• Glycoprotein IIb/IIIa receptor antagonists: a comparative review of their use in percutaneous coronary intervention.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20030101

• Benefit of an early invasive management strategy in women with acute coronary syndromes.

  JAMA 20021225

• Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban.

  The American journal of cardiology 20021215

• Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion.

  The Journal of pharmacology and experimental therapeutics 20021201

• Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial).

  The American journal of cardiology 20021201

• Platelets: is aspirin sufficient or must we know how to pronounce abciximab?

  Seminars in vascular surgery 20021201

• TARGET follow-up study.

  Lancet (London, England) 20021201

• The complementary use of glycoprotein IIb/IIIa inhibitors and drug-eluting stents in contemporary percutaneous coronary intervention.

  The Journal of invasive cardiology 20021201

• Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials.

  Journal of thrombosis and thrombolysis 20021201

• Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy- Thrombolysis in Myocardial Infarction 18 trial)substudy.

  Journal of the American College of Cardiology 20021120

• Defining optimal therapy for the thrombolysis-ineligible patient.

  Clinical cardiology 20021101

• Decrease of vascular smooth muscle cell locomotion by abciximab, but not tirofiban: a possible role of different affinity to alpha v beta 3 integrins.

  Coronary artery disease 20021101

• Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction.

  JAMA 20021016

• ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina).

  Circulation 20021001

• No evidence for an influence of the human platelet antigen-1 polymorphism on the antiplatelet effects of glycoprotein IIb/IIIa inhibitors.

  Pharmacogenetics 20021001

• Percutaneous femoral artery angioplasty with stent-in-stent technique and tirofiban administration.

  The Journal of invasive cardiology 20021001

• [Stratification of cardiac risk in unstable angina: value of troponin measurements].

  La Tunisie medicale 20021001

• Human thrombocytes are able to induce a myocardial dysfunction in the ischemic and reperfused guinea pig heart mediated by free radicals-role of the GPIIb/IIIa-blocker tirofiban.

  Life sciences 20020927

• Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.

  Circulation 20020917

• Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.

  Blood 20020915

• Efficacy and safety of multivessel percutaneous revascularization and tirofiban therapy in patients with acute coronary syndromes.

  The American journal of cardiology 20020915

• Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study).

  The American journal of cardiology 20020901

• Molecular mechanisms of platelet-mediated leukocyte recruitment during myocardial reperfusion.

  Journal of leukocyte biology 20020901

• Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin.

  American heart journal 20020901

• Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial).

  Journal of the American College of Cardiology 20020821

• Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study.

  Lancet (London, England) 20020803

• Platelet inhibition with tirofiban early during percutaneous coronary intervention: dosing revisited.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20020801

• Anti-platelet effects of GPIIb/IIIa and P-selectin antagonism, platelet activation, and binding to neutrophils.

  Journal of cardiovascular pharmacology 20020801

• A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement.

  Clinical therapeutics 20020801

• Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates.

  Journal of thrombosis and thrombolysis 20020801

• Platelet glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: IIb or Not IIb, what is the question?

  The Journal of invasive cardiology 20020701

• Optimizing glycoprotein IIb/IIIa inhibition: lessons from recent randomized controlled trials.

  Internal medicine journal 20020701

• Correlates of coronary blood flow before and after percutaneous coronary intervention and their relationship to angiographic and clinical outcomes in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis.

  American heart journal 20020701

• [Platelet antiaggregation treatment in the aftermath of GUSTO IV, TARGET, TACTICS, and CURE trials].

  Revista espanola de cardiologia 20020701

• TARGET versus GUSTO-IV: appropriate use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes and percutaneous coronary intervention.

  Current opinion in cardiology 20020701

• Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up.

  Circulation 20020611

• Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention.

  The American journal of cardiology 20020601

• The TARGET trial: hit or miss?

  European heart journal 20020601

• Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial.

  Circulation 20020521

• Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial.

  Circulation 20020521

• Images in cardiology. Glycoprotein IIb/IIIa induced coronary thrombolysis.

  Heart (British Cardiac Society) 20020501

• Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions.

  Critical care medicine 20020501

• Tirofiban blocks platelet adhesion to fibrin with minimal perturbation of GpIIb/IIIa structure.

  Thrombosis and haemostasis 20020501

• Antithrombotic agents: implications in dentistry.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20020501

• MK-383 (tirofiban) induces a GPIIb/IIIa receptor conformation which differs from the resting and activated receptor.

  Platelets 20020501

• Comparative antithrombotic effects of magnesium sulfate and the platelet glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide in a canine model of stent thrombosis.

  Circulation 20020423

• Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors.

  The American journal of cardiology 20020415

• Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies.

  Thrombosis research 20020415

• Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition.

  American heart journal 20020401

• Cost efficacy of platelet glycoprotein IIb/IIIa antagonists in clinical trials and clinical practice.

  Journal of interventional cardiology 20020401

• Vertebrobasilar thrombolysis with intravenous tirofiban: case report.

  Journal of thrombosis and thrombolysis 20020401

• Low incidence of paradoxical platelet activation by glycoprotein IIb/IIIa inhibitors.

  Thrombosis research 20020401

• Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions.

  The American journal of cardiology 20020301

• [Pilot study of the effectiveness of combination therapy with reduced dose alteplase and the glycoprotein IIb/IIIa antagonist tirofiban in acute myocardial infarct].

  Zeitschrift fur Kardiologie 20020301

• Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta3 integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin.

  Circulation 20020212

• Ischemic brain tissue salvaged from infarction by the GP IIb/IIIa platelet antagonist tirofiban.

  Neurology 20020212

• An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.

  European heart journal 20020201

• The role of alpha(v)beta3 integrins in vascular healing.

  Thrombosis and haemostasis 20020201

• Activated recombinant factor VII (rFVIIa) in bleeding management after therapy with IIb/IIIa-inhibitor tirofiban.

  Thrombosis and haemostasis 20020201

• Glycoprotein IIb/IIIa inhibitors.

  Intensive & critical care nursing 20020201

• The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors.

  Journal of interventional cardiology 20020201

• Cost effectiveness of invasive strategy in unstable coronary disease--what are we waiting for?

  European heart journal 20020101

• Hypothermia-induced platelet aggregation in heparinized flowing human blood: identification of a high responder subpopulation.

  American journal of hematology 20020101

• Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab.

  Clinical pharmacokinetics 20020101

• Inhibition of shear-stress-induced platelet aggregation and phosphotyrosine signaling by GPIIb-IIIa antagonists.

  Annals of biomedical engineering 20020101

• Emergency coronary artery bypass surgery in the era of glycoprotein IIb/IIIa receptor antagonist use.

  Journal of cardiac surgery 20020101

• Current management of unstable angina: lessons from the TACTICS-TIMI 18 trial.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20020101

• Platelet inhibition after glycoprotein IIb/IIIa inhibitor therapy.

  Circulation 20011218

• Glycoprotein IIb/IIIa receptor blockers in acute coronary syndromes.

  Lancet (London, England) 20011208

• Standardized ultrasound as a new method to induce platelet aggregation: evaluation, influence of lipoproteins and of glycoprotein IIb/IIIa antagonist tirofiban.

  European journal of ultrasound : official journal of the European Federation of Societies for Ultrasound in Medicine and Biology 20011201

• Treatment of acute basilar artery thrombosis with a combination of systemic alteplase and tirofiban, a nonpeptide platelet glycoprotein IIb/IIIa inhibitor: report of four cases.

  Radiology 20011201

• Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting.

  The Journal of thoracic and cardiovascular surgery 20011201

• One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II.

  The Journal of thoracic and cardiovascular surgery 20011201

• A risk stratification scheme for selection of a glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention based on clinical and angiographic criteria.

  The American journal of cardiology 20011201

• Cost implications of routine tirofiban use in the management of acute coronary syndromes.

  International journal of cardiology 20011201

• GP IIb/IIIa inhibitors in coronary artery disease management: what the latest trials tell us.

  Cleveland Clinic journal of medicine 20011201

• Synthesis of RGD analogs as potential vectors for targeted drug delivery.

  Bioorganic chemistry 20011201

• Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes.

  The New England journal of medicine 20011122

• Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes.

  The New England journal of medicine 20011122

• Acute coronary syndrome without ST elevation: implementation of new guidelines.

  Lancet (London, England) 20011103

• ESPRIT in context: pharmacology matters!

  European heart journal 20011101

• Small peptide GP IIb/IIIa receptor inhibitors as upstream therapy in non-ST-segment elevation acute coronary syndromes: results of the PURSUIT, PRISM, PRISM-PLUS, TACTICS, and PARAGON trials.

  Current opinion in cardiology 20011101

• Use of coronary revascularization in patients with unstable and non-ST-segment elevation acute myocardial infarction.

  The American journal of cardiology 20011018

• Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban).

  The American journal of cardiology 20011015

• A comparison of total hospital costs for percutaneous coronary intervention patients receiving abciximab versus tirofiban.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20011001

• Stability of tirofiban hydrochloride in 0.9% sodium chloride injection for 30 days.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20011001

• Increased reperfusion by glycoprotein IIb/IIIa receptor antagonist administration in case of unsuccessful and failed thrombolysis in patients with acute myocardial infarction: a pilot study.

  Italian heart journal : official journal of the Italian Federation of Cardiology 20011001

• [Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban].

  Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology 20011001

• [Comparison of 2 platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization].

  Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology 20011001

• Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban.

  Journal of thrombosis and thrombolysis 20011001

• Differential inhibition of adenosine diphosphate- versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics.

  Blood 20010901

• A risk score system for predicting adverse outcomes and magnitude of benefit with glycoprotein IIb/IIIa inhibitor therapy in patients with unstable angina pectoris.

  The American journal of cardiology 20010901

• Adjunctive therapies in the cath lab. Combination of tirofiban and alteplase in acute myocardial infarction.

  The Journal of invasive cardiology 20010901

• Adjunctive therapies in the cath lab. Intracoronary tirofiban infusion in a case with massive intracoronary thrombus.

  The Journal of invasive cardiology 20010901

• Adjunctive therapies in the cath lab. Use of combination glycoprotein IIb/IIIa inhibitor and direct thrombin inhibitor drugs to support percutaneous coronary stent placement in a patient with renal insufficiency and heparin-induced thrombocytopenia.

  The Journal of invasive cardiology 20010901

• Tirofiban therapy does not increase the risk of hemorrhage after emergency coronary surgery.

  The Journal of thoracic and cardiovascular surgery 20010901

• Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects.

  British journal of clinical pharmacology 20010901

• Alternatives to unfractionated heparin for anticoagulation in cardiopulmonary bypass.

  Perfusion 20010901

• Resolution of a spontaneous coronary artery thrombus with a new antiplatelet agent.

  International angiology : a journal of the International Union of Angiology 20010901

• ReoPro rules: results from the 'Do Tirofiban and ReoPro Give Similar Efficacy Trial' (TARGET).

  Expert opinion on pharmacotherapy 20010901

• Should patients with unstable coronary syndromes routinely undergo cardiac catheterization and appropriate revascularization?

  The Journal of family practice 20010901

• [Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization].

  Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology 20010901

• Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa (alphaIIb/beta3) receptor-directed platelet inhibition.

  American heart journal 20010801

• The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy.

  American heart journal 20010801

• Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method.

  British journal of pharmacology 20010801

• Safety and efficacy of thrombolysis with alteplase (50 mg) plus tirofiban versus alteplase (100 mg) alone in acute myocardial infarction: preliminary findings.

  Italian heart journal : official journal of the Italian Federation of Cardiology 20010801

• Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population.

  Circulation 20010731

• Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin.

  Circulation 20010731

• Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20010701

• Glycoprotein IIb/IIIa inhibitors: more different than alike?

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20010701

• Use of ICHOR-platelet works to assess platelet function in patients treated with GP IIb/IIIa inhibitors.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20010701

• Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.

  The New England journal of medicine 20010621

• Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.

  The New England journal of medicine 20010621

• Future trials of antiplatelet agents in cardiac ischemia.

  The New England journal of medicine 20010621

• Optimal treatment of acute coronary syndromes--an evolving strategy.

  The New England journal of medicine 20010621

• [Lysis of an extensive thrombus in the internal carotid artery using a glycoprotein IIb/IIIa receptor antagonist].

  Deutsche medizinische Wochenschrift (1946) 20010608

• Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy.

  Circulation 20010529

• Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.

  Circulation 20010529

• Effects on thrombin generation of the platelet glycoprotein IIb/IIIa inhibitors abciximab versus tirofiban during coronary intervention.

  The American journal of cardiology 20010515

• Exit of platelet glycoprotein-IIb/IIIa-receptor inhibitors?

  Lancet (London, England) 20010512

• Quantification by flow cytometry of the efficacy of and interindividual variation of platelet inhibition induced by treatment with tirofiban and abciximab.

  Coronary artery disease 20010501

• Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes.

  Cardiology clinics 20010501

• Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.

  Journal of thrombosis and thrombolysis 20010501

• Elevation in serum troponin I predicts the benefit of tirofiban.

  Journal of thrombosis and thrombolysis 20010501

• Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist.

  Thrombosis research 20010415

• A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20010401

• Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting.

  Journal of the American College of Cardiology 20010401

• [Risk stratification in acute coronary syndrome].

  Herz 20010401

• [Pathophysiology of platelet activation and pharmacology of GPIIb/IIIa inhibitors].

  Herz 20010401

• [GPIIb-IIIa inhibitors].

  Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine 20010401

• Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.

  Journal of thrombosis and thrombolysis 20010401

• New approaches to diagnosis and management of unstable angina and non-ST-segment elevation myocardial infarction.

  Archives of internal medicine 20010312

• Platelet glycoprotein IIb/IIIa receptor antagonists and coronary artery disease.

  Current atherosclerosis reports 20010301

• Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention.

  The American journal of cardiology 20010301

• Impact of abciximab versus tirofiban on hospital length of stay for PCI patients.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20010301

• Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.

  Thrombosis and haemostasis 20010301

• Unexpected flow cytometric results with two small GPIIb/IIIa blockers: eptifibatide and tirofiban.

  Thrombosis and haemostasis 20010301

• [Acute coronary syndromes: an update. I. Pathogenesis and drug therapy].

  Herz 20010301

• Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function.

  Journal of the American College of Cardiology 20010301

• Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management. PRISM-PLUS Investigators.

  The American journal of cardiology 20010215

• Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban.

  Anesthesiology 20010201

• [Tirofiban (Aggrastat). A non-peptide glycoprotein IIb/IIIa receptor inhibitor].

  Ugeskrift for laeger 20010122

• [Update on tirofiban].

  Presse medicale (Paris, France : 1983) 20010120

• Complicated acute myocardial infarction.

  The Journal of emergency medicine 20010101

• [Update on the treatment with platelet antiaggregation agents].

  Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology 20010101

• Tirofiban administration attenuates platelet and platelet-neutrophil conjugation but not neutrophil degranulation during in vitro VAD circulation.

  ASAIO journal (American Society for Artificial Internal Organs : 1992) 20010101

• [Inhibitors of platelet glycoprotein IIb-IIIa in cardiology].

  Vojnosanitetski pregled 20010101

• TACTICS-TIMI 18 shows positive results of invasive approach.

  Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20010101

• The role of glycoprotein IIb/IIIa inhibition in the management of acute coronary syndromes.

  Heart & lung : the journal of critical care 20010101

• Bleeding risk of tirofiban, a nonpeptide GPIIb/IIIa platelet receptor antagonist in progressive stroke: an open pilot study.

  Cerebrovascular diseases (Basel, Switzerland) 20010101

• Intravenous glycoprotein IIb/IIIa inhibition in non-ST segment elevation acute coronary syndromes.

  Progress in cardiovascular diseases 20010101

• [Glycoprotein IIb/IIIa inhibitors in unstable angina].

  Annales de cardiologie et d'angeiologie 20010101

• Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials.

  The American journal of medicine 20000815